Analyst Etzer Darout of BMO Capital maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of $89.00.

AstraZeneca (GB:AZN) has released an update. AstraZeneca remains committed to delivering its innovative medicines in China despite ongoing ...

AstraZeneca Plc shares plunged in London, erasing about £14 billion ($18 billion) of market value, amid escalating concerns ...

AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...

Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...

AstraZeneca's (NASDAQ:AZN) selloff on Tuesday in response to reports that the company is facing a fraud investigation in ...

AstraZeneca shares recorded their biggest one-day drop since March 2020 on Tuesday following a report that dozens of senior ...

AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated in an insurance ...

AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially ...

AstraZeneca shares fell 8% in London Tuesday, the biggest drop in four years following a fresh report that a Chinese investigation of the company has widened. AstraZeneca said last week that its China ...

Scientists at the Johns Hopkins Kimmel Cancer Center have identified 16 genes that breast cancer cells use to survive in the bloodstream after they've escaped the low-oxygen regions of a tumor.

Primark boss says weight of Budget tax rises ‘falling on high street’ The boss of Primark said the 'weight of tax rises' in ...